nebivolol (Bystolic)
Jump to navigation
Jump to search
Introduction
Tradename: Bystolic. FDA approved 2007
Indications
- hypertension
- angina pectoris[2]
- chronic heart failure
- rate control in atrial fibrillation
- secondary prevention in patients with cardiovascular disease[2]
Adverse effects
- drug adverse effects of beta-adrenergic receptor antagonists
- drug adverse effects of beta-1 adrenergic receptor antagonists
- drug adverse effects of renin-angiotensin-aldosterone system inhibitors (RAAS inhibitors)
- drug adverse effects of antihypertensive agents
Mechanism of action
More general terms
Component of
References
- ↑ Weiss RJ et al, A randomized, double-blind, placebo-controlled parallel group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension J Clin Hypertens 2007, 9:667 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17786067
- ↑ 2.0 2.1 2.2 Deprecated Reference